SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001069530-20-000066
Filing Date
2020-11-09
Accepted
2020-11-09 07:43:04
Documents
48
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q sava-20200930x10q.htm 10-Q 947666
2 EX-31.1 sava-20200930xex31_1.htm EX-31.1 25505
3 EX-31.2 sava-20200930xex31_2.htm EX-31.2 25204
4 EX-32.1 sava-20200930xex32_1.htm EX-32.1 20325
  Complete submission text file 0001069530-20-000066.txt   3823755

Data Files

Seq Description Document Type Size
5 EX-101.INS sava-20200930.xml EX-101.INS 830905
6 EX-101.SCH sava-20200930.xsd EX-101.SCH 27756
7 EX-101.CAL sava-20200930_cal.xml EX-101.CAL 29918
8 EX-101.DEF sava-20200930_def.xml EX-101.DEF 65659
9 EX-101.LAB sava-20200930_lab.xml EX-101.LAB 202869
10 EX-101.PRE sava-20200930_pre.xml EX-101.PRE 172187
Mailing Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731
Business Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

IRS No.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-29959 | Film No.: 201296124
SIC: 2834 Pharmaceutical Preparations